Trial Profile
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Durvalumab; Pembrolizumab; Sintilimab; Tislelizumab; Toripalimab
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 22 Mar 2023 Status changed from recruiting to completed.
- 06 Oct 2022 Planned number of patients changed from 40 to 100.
- 06 Oct 2022 Planned End Date changed from 31 Oct 2027 to 31 Oct 2031.